IPO registrations (S-1, F-1) · Registrants
LeonaBio, Inc.
- SEC CIK
- 1620463 · filings on EDGAR ↗
- Former names
- Athira Pharma, Inc. (2019–2026); M3 Biotechnology, Inc. (2014–2019)
- Registration
- Form S-1, first filed 2020-08-26, last 2026-03-31; 2 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2020-09-18; declared effective 2020-09-17
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, Bothell, WA 98011
- EIN
- 45-3368487
- Ticker
- LONA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- LeonaBio, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2020-09-17)
- Final price
- $17.00 per share, within the range (424B4 filed 2020-09-18, an initial public offering)
- Shares sold
- 12,000,000
- Gross proceeds
- $204,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ATHA
- Lead underwriters
- Goldman Sachs; Jefferies
- Syndicate
- Stifel; JMP Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: LeonaBio, Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: LEONABIO, INC. EXACT (EIN (EXACT))
- Form D issuer: Athira Pharma, Inc. EXACT (CIK (EXACT))
- SEC filer: Athira Pharma, Inc. EXACT (CIK (EXACT))
- Person page: John M Fluke Jr Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 16
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-08-26 | S-1 | S-1 (registration) | Athira Pharma, Inc. | 0001564590-20-041369 ↗ |
| 2020-09-09 | S-1/A | S-1/A (amendment) | Athira Pharma, Inc. | 0001564590-20-042848 ↗ |
| 2020-09-14 | S-1/A | S-1/A (amendment) | Athira Pharma, Inc. | 0001564590-20-043324 ↗ |
| 2020-09-17 | S-1/A | S-1/A (amendment) | Athira Pharma, Inc. | 0001564590-20-043758 ↗ |
| 2020-09-17 | S-1MEF | S-1MEF (added securities) | Athira Pharma, Inc. | 0001564590-20-043890 ↗ |
| 2020-09-17 | EFFECT | EFFECT (declared effective) | Athira Pharma, Inc. | 9999999995-20-002483 ↗ |
| 2020-09-18 | 424B4 | 424B4 (final prospectus) | Athira Pharma, Inc. | 0001564590-20-043998 ↗ |
| 2021-01-19 | S-1 | S-1 (registration) | Athira Pharma, Inc. | 0001564590-21-001397 ↗ |
| 2021-01-20 | EFFECT | EFFECT (declared effective) | Athira Pharma, Inc. | 9999999995-21-000203 ↗ |
| 2021-01-21 | 424B4 | 424B4 (final prospectus) | Athira Pharma, Inc. | 0001564590-21-001770 ↗ |
| 2021-11-24 | EFFECT | EFFECT (declared effective) | Athira Pharma, Inc. | 9999999995-21-004485 ↗ |
| 2024-10-28 | EFFECT | EFFECT (declared effective) | Athira Pharma, Inc. | 9999999995-24-003298 ↗ |
| 2026-03-31 | S-1/A | S-1/A (amendment) | LeonaBio, Inc. | 0001193125-26-134866 ↗ |
| 2026-03-31 | S-1/A | S-1/A (amendment) | LeonaBio, Inc. | 0001193125-26-134904 ↗ |
| 2026-04-01 | EFFECT | EFFECT (declared effective) | LeonaBio, Inc. | 9999999995-26-001045 ↗ |
| 2026-04-01 | EFFECT | EFFECT (declared effective) | LeonaBio, Inc. | 9999999995-26-001046 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-17 | S-1/A | registration statement | $15.00–$17.00 | 10,000,000 | - | Nasdaq ATHA | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2020-09-18 | 424B4 | final prospectus | $17.00 | 12,000,000 | $204,000,000 | Nasdaq ATHA | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| CHURCH KEVIN | Officer | Chief Scientific Officer; CHIEF SCIENTIFIC OFFICER; Executive VP, Research; Vice President of Discovery | 23 | 2020–2026 | |
| EDELMAN JOSEPH | Director; Director,TenPercentOwner | 15 | 2020–2026 | ||
| JOHNSON JAMES A | Director | 9 | 2020–2026 | ||
| KAWAS LEEN | Director,Officer; Director,Officer,TenPercentOwner | President & CEO | 2 | 2020–2021 | |
| Litton Mark James | Director,Officer; Officer | CEO; Chief Executive Officer; Chief Operating Officer; President and CEO; PRESIDENT and CEO | 20 | 2020–2026 | |
| MILESON GLENNA | Officer | Chief Financial Officer | 9 | 2020–2023 | |
| MOEBIUS HANS | Officer | Chief Medical Officer | 11 | 2020–2024 | |
| PERCEPTIVE ADVISORS LLC | Director; Director,TenPercentOwner; TenPercentOwner | 10 | 2020–2026 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director; Director,TenPercentOwner; TenPercentOwner | 10 | 2020–2026 | ||
| RTW INVESTMENTS, LP | TenPercentOwner | 2 | 2020 | ||
| WONG RODERICK | TenPercentOwner | 2 | 2020 | ||
| Yamada Tadataka | Director | 2 | 2020–2021 | ||
| FLUKE JOHN M JR | Director | 10 | 2020–2026 | person page Fuzzy | |
| Romano Kelly A | Director | 12 | 2020–2026 | ||
| Kosacz Barbara | Director | 8 | 2021–2026 | ||
| Worthington Mark | Officer | General Counsel; GENERAL COUNSEL; General Counsel and CCO; GENERAL COUNSEL and CCO | 17 | 2021–2026 | |
| Lenington Rachel | Officer | Chief Operating Officer; Chief Technology Officer; COO and CDO; COO AND CDO | 9 | 2021–2024 | |
| PICKERING GRANT | Director | 10 | 2022–2026 | ||
| Panzara Michael A. | Director | 8 | 2022–2026 | ||
| Gengos Andrew | Officer | CFO and Chief Business Officer; CFO AND CHIEF BUSINESS OFFICER; See Below | 8 | 2023–2024 | |
| San Martin Javier | Officer | CHIEF MEDICAL OFFICER | 10 | 2024–2026 | |
| Renninger Robert | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER; SVP, Finance and Accounting; VP of Finance | 10 | 2024–2026 | |
| Perceptive Xontogeny Venture Fund II, LP | Director,TenPercentOwner | 1 | 2025 | ||
| Callori Fred | Director | 3 | 2026 | ||
| Holles Natalie C. | Director | 3 | 2026 | ||
| Silverman Peter B. | Director | 3 | 2026 | ||
| Portman David J. | TenPercentOwner | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-06-12 | Athira Pharma, Inc. | Biotechnology | $90,944,020 | $89,007,350 | 73 | 1 |
| 2018-12-20 | Athira Pharma, Inc. | Biotechnology | $4,650,000 | $3,816,000 | 22 | 4 |
| 2015-11-20 | M3 Biotechnology, Inc. | Biotechnology | $17,000,000 | $14,115,000 | 41 | 3 |
| 2014-10-03 | M3 Biotechnology, Inc. | Other | $1,200,000 | $350,000 | 7 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | LeonaBio, Inc. | WA | State business registries | name and state |
| Plan sponsor | LEONABIO, INC. | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Athira Pharma, Inc. | WA | Form D private offerings | CIK (EXACT) |
| SEC filer | LeonaBio, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | LEONABIO, INC. | WA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | LEONABIO, INC. | EIN (EXACT) | ||
| Person page | John M Fluke Jr | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), WA first:
- CORIXA CORP WA
- Seagen Inc. WA
- ZYMOGENETICS INC WA
- NS Wind Down Co., Inc. WA
- Adaptive Biotechnologies Corp WA
- Juno Therapeutics, Inc. WA
- Sana Biotechnology, Inc. WA
- Icosavax, Inc. WA
- Intrinsic Medicine, Inc. WA
- Aurion Biotech, Inc. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health